The Synthesis of Nano-Doxorubicin and its Anticancer Effect
1Department of Science and Research, Taizhou People's Hospital, The Fifth Affiliated Hospital of Nantong University, Taizhou 225300, China.
Abstract:
Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due to the lack of tumor specificity of the drug and severe side effects such as myelosuppression, nephrotoxicity, dose-dependent cardiotoxicity, and multi-drug resistance. To improve the bioavailability of DOX, maximize the therapeutic effect, and reduce its toxicity and side effects, many studies have been done on the nanoformulations of DOX, such as liposomes, polymer micelles, dendrimer, and nanogels. Herein, we review the latest progress of DOX nano-preparations and their anti-tumor effects, hoping to provide theoretical references and new research ideas for the development of new dosage forms of the drug and the technical methods available for clinical application.
Insights
Doxorubicin (DOX) nanoformulations enhance anti-cancer drug delivery, improving efficacy and reducing side effects. This review covers recent advancements in DOX nano-preparations for better tumor targeting and treatment.
Area of Science:
- Oncology
- Nanomedicine
- Pharmacology
Background:
- Doxorubicin (DOX) is a vital first-line chemotherapy agent.
- Clinical use is hindered by poor tumor specificity, leading to severe side effects like cardiotoxicity and myelosuppression.
- Multi-drug resistance further complicates DOX treatment efficacy.
Purpose of the Study:
- To review recent advancements in Doxorubicin nanoformulations.
- To evaluate the anti-tumor effects of these nano-preparations.
- To offer insights for developing novel DOX dosage forms and clinical applications.
Main Methods:
- Literature review of Doxorubicin nanoformulations.
- Analysis of studies on liposomes, polymer micelles, dendrimers, and nanogels.
- Evaluation of reported anti-tumor efficacy and toxicity profiles.
Main Results:
- Various nanoformulations show improved Doxorubicin bioavailability and tumor targeting.
- Reduced systemic toxicity and enhanced therapeutic outcomes are observed with nano-encapsulated DOX.
- Nano-preparations demonstrate potential in overcoming multi-drug resistance.
Conclusions:
- Doxorubicin nanoformulations represent a promising strategy to enhance anti-cancer therapy.
- Further research into nano-delivery systems can optimize DOX's therapeutic index.
- These advancements pave the way for improved clinical applications of Doxorubicin.
